{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:08:41Z","timestamp":1792202921872,"version":"4.4.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1016\/j.jaad.2007.08.039","type":"journal-article","created":{"date-parts":[[2007,10,5]],"date-time":"2007-10-05T14:21:22Z","timestamp":1191594082000},"page":"33-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":382,"title":["Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study"],"prefix":"10.1016","volume":"58","author":[{"given":"J\u00fcrgen","family":"Schneck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Fagot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Sekula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Sassolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Claude","family":"Roujeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Mockenhaupt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2007.08.039_bib1","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(97)11369-1","article-title":"Toxic epidermal necrolysis","volume":"351","author":"Becker","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2007.08.039_bib2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2133.2005.06721.x","article-title":"Toxic epidermal necrolysis: current evidence, practical management and future directions","volume":"153","author":"Chave","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2007.08.039_bib3","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1056\/NEJMcpc059029","article-title":"Case records of the Massachusetts General Hospital, case 34-2005: a 10-year-old girl with a bullous skin eruption and acute respiratory failure","volume":"353","author":"Sheridan","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2007.08.039_bib4","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","article-title":"Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study","volume":"138","author":"Auquier-Dunant","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2007.08.039_bib5","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2007.08.039_bib6","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"A clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2007.08.039_bib7","first-page":"143","article-title":"Cutaneous adverse drug reactions. Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Mockenhaupt","year":"2002","journal-title":"ACI International"},{"key":"10.1016\/j.jaad.2007.08.039_bib8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2007.08.039_bib9","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.jid.5700068","article-title":"Performance of SCORTEN during the first five days of hospitalization to predict the prognosis of toxic epidermal necrolysis","volume":"126","author":"Guegan","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2007.08.039_bib10","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-4362.1989.tb02502.x","article-title":"Drug-induced toxic epidermal necrolysis treated with cyclosporin","volume":"28","author":"Renfro","year":"1989","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2007.08.039_bib11","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0190-9622(08)80969-3","article-title":"Efficacy of cyclophosphamide in toxic epidermal necrolysis, clinical and pathophysiologic aspects","volume":"25","author":"Heng","year":"1991","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2007.08.039_bib12","first-page":"473","article-title":"Treatment of toxic epidermal necrolysis with cyclosporin A","volume":"48","author":"Arevalo","year":"2000","journal-title":"J\u00a0Trauma"},{"key":"10.1016\/j.jaad.2007.08.039_bib13","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00000658-198611000-00001","article-title":"Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids","volume":"204","author":"Halebian","year":"1986","journal-title":"Ann Surg"},{"key":"10.1016\/j.jaad.2007.08.039_bib14","first-page":"273","article-title":"Burn center care for patients with toxic epidermal necrolysis","volume":"180","author":"Kelemen","year":"1995","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.jaad.2007.08.039_bib15","first-page":"340","article-title":"Toxic epidermal necrolysis, a systemic and dermatologic disorder best treated with standard treatment protocols in burn intensive care units without the prolonged use of corticosteroids","volume":"180","author":"Herndon","year":"1995","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.jaad.2007.08.039_bib16","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","article-title":"Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis","volume":"352","author":"Wolkenstein","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2007.08.039_bib17","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockage of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jaad.2007.08.039_bib18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000051702","article-title":"Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience","volume":"203","author":"Stella","year":"2001","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2007.08.039_bib19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archderm.139.1.26","article-title":"Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases","volume":"139","author":"Prins","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2007.08.039_bib20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.139.1.33","article-title":"Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"139","author":"Bachot","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2007.08.039_bib21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/archderm.139.1.39","article-title":"Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN\u2013the University of Miami experience","volume":"139","author":"Trent","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2007.08.039_bib22","first-page":"430","article-title":"High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis","volume":"83","author":"Campione","year":"2003","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2007.08.039_bib23","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000070957","article-title":"Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective multicenter study","volume":"207","author":"Prins","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2007.08.039_bib24","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.BCR.0000105096.93526.27","article-title":"Toxic epidermal necrolysis: does immunoglobulin make a difference?","volume":"25","author":"Brown","year":"2004","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.jaad.2007.08.039_bib25","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.BCR.0000124746.33279.86","article-title":"Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis","volume":"25","author":"Shortt","year":"2004","journal-title":"J Burn Care Rehabil"},{"key":"10.1016\/j.jaad.2007.08.039_bib26","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.2165\/00003495-200565150-00002","article-title":"Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IVIg): clinical experience to date","volume":"65","author":"Faye","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.jaad.2007.08.039_bib27","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00130832-200308000-00006","article-title":"Intravenous immunoglobulins in the treatment of severe drug eruptions","volume":"3","author":"Bachot","year":"2003","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2007.08.039_bib28","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.intimp.2005.11.012","article-title":"Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: Our current understanding","volume":"6","author":"French","year":"2006","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaad.2007.08.039_bib29","doi-asserted-by":"crossref","unstructured":"Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavnick JN, et\u00a0al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risk with emphasis on recently marketed drugs: the EuroSCAR-study. J\u00a0Invest Dermatol doi:10.1038\/sj.jid.5701033. Published online September 6, 2007.","DOI":"10.1038\/sj.jid.5701033"},{"key":"10.1016\/j.jaad.2007.08.039_bib30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/archderm.139.1.85","article-title":"Treatment of toxic epidermal necrolysis: the uncertainty persists but the fog is dispersing","volume":"139","author":"Wolff","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2007.08.039_bib31","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2007.08.039_bib32","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaci.2004.07.047","article-title":"Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells","volume":"114","author":"Nassif","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2007.08.039_bib33","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/eji.200425773","article-title":"Prevention of toxic epidermal necrolysis by regulatory T cells","volume":"35","author":"Azukizawa","year":"2005","journal-title":"Eur J\u00a0Immunol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962207013266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962207013266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:07:39Z","timestamp":1759270059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962207013266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["S0190962207013266"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2007.08.039","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2008,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2007.08.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}